Enterprise Value
32.62M
Cash
51.12M
Avg Qtr Burn
-1.791M
Short % of Float
0.62%
Insider Ownership
24.24%
Institutional Own.
29.61%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NexoBrid Details Eschar removal, Thermal burns | Approved Quarterly sales | |
EscharEx Details Venous Leg Ulcers | Phase 3 Initiation | |
MW005 Details Basal cell carcinoma, Cancer, Non-melanoma skin cancer, Skin cancer | Phase 1/2 Data readout |